Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Knowing when to save money and when to invest is vital for financial success. This article provides insights on timing your decisions.
28,655 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
OpenAI is nearing a private funding round that could push its valuation above $850 billion, a level that would outstr...
AI data centers are expanding rapidly, yet a constrained pool of electricians threatens timelines. Gen Z is increasin...
The FAA has halted all JetBlue flights at the airline’s request, triggering widespread travel disruption and a swift ...
A swift flow of inflation signals can reshape markets. This guide explains what to watch, how inflation could unfold,...
The telehealth name Hims & Hers Health tumbled after a disappointing quarter. This piece breaks down what happened, w...
As 2026 unfolds, investors debate what’s best crypto between XRP, Solana and BNB, weighing use cases, network upgrade...
Nvidia is moving from data centers to the PC desk. This shift could redefine competitive dynamics among Intel, AMD, a...
RH has endured a steep decline over five years. This article breaks down whether the luxury home brand can stage a re...
A seven-year high in regional bank M&A signals bigger players aiming for scale and efficiency. This guide breaks down...
When a biotech firm nears a major FDA decision, every insider transaction can feel like a tell. This article dives in...
A week after Walmart’s investor day, the stock surged as analysts highlighted margin discipline and cash returns. Thi...